Reaxys Medicinal Chemistry Now Offers the World’s Largest Medicinal Chemistry Database
AMSTERDAM, May 12, 2014 /PRNewswire/ –
Reaxys Medicinal Chemistry enables scientists to explore new drug candidates
through a comprehensive database with new search features, refined user-interface and
integration with Reaxys
Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, today announced that Reaxys Medicinal
Chemistry offers the world’s largest medicinal chemistry database. Reaxys Medicinal
Chemistry enables researchers to quickly and confidently identify the most promising
compounds to take forward in the drug discovery process by covering critical areas for
medicinal chemistry research, including in vivo animal studies, in vitro efficacy, drug
pharmacokinetics and toxicity data.
The Reaxys Medicinal Chemistry database contains 25 million bioactivity data points,
making it the largest such dataset, with corresponding bioassays on 5.1 million unique
substances compiled from 320,000 medicinal chemistry publications and patents, fully
indexed and normalized.
Users who subscribe to both Reaxys and Reaxys Medicinal Chemistry will have a
comprehensive view of the most relevant bioactivity data and be able to explore the
structures and physiochemical properties of other known compounds, via a single integrated
interface. With access to the automatic synthesis pathway generator, users can immediately
start to work on selected substances. This will facilitate workflows from lead
identification to compound synthesis and enable scientists to generate new drug ideas by
exploring the chemical space of new compounds.
Additional new features include:
- Flexible search options - users are now able to choose from bioactivity, substance and literature query themes. The new search interface supports text and chemical structure-based input and dedicated filters allow users to refine results. - Heatmap view - provides an overview of the relationships between substances and targets in terms of various parameters; allowing rapid identification of the most relevant compound-target relationships. Users can compare bioactivity data from different publications and assay types, using pX values, aiding the discovery of connections between bioactive compounds and targets. - Improved sharing and integration - flexible export of search results in multiple, compatible formats that are easily shared with fellow researchers. In addition, the availability of APIs and SAR Flat File facilitate integration with enterprise systems.
“Chemists in Pharma face many challenges when it comes to developing a drug. They need
to understand the relationship between structural functions of a substance and their
activity against identified targets, find compounds showing similar activity features to
identify the chemical space to move in and synthesize promising candidates,” said Juergen
Swienty-Busch, Director Product Management Chemistry (Reaxys), Elsevier. “This typically
requires extensive literature research using many tools and databases with challenges
around collecting and comparing data. However, Reaxys and Reaxys Medicinal Chemistry
together provide an integrated solution allowing analysis and identification of lead
candidates as well as information about synthesis, reactions and physicochemical
properties. This product integration reflects how Elsevier’s Life Science Solutions
portfolio addresses the needs of researchers in drug discovery and development.”
Reaxys Medicinal Chemistry customers upgraded to the latest version on May 11th. For
more information on Reaxys Solutions, go to
Reaxys(R) is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys(R) combines reaction and substance data in
organic, organometallic, inorganic and physical chemistry with synthesis planning.
Researchers can get the information they need in a single overview, from source
publications carefully selected for their importance and relevance to research chemists.
Elsevier continues to engage with the chemistry community to ensure that Reaxys(R)
continues to reflect how chemists think and work. For more information go to Reaxys
Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA
and used under license.
Elsevier is a world-leading provider of information solutions that enhance the
performance of science, health, and technology professionals, empowering them to make
better decisions, deliver better care, and sometimes make groundbreaking discoveries that
advance the boundaries of knowledge and human progress. Elsevier provides web-based,
digital solutions – among them ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Elsevier Research Intelligence
[http://www.elsevier.com/online-tools/research-intelligence ] and ClinicalKey
[https://www.clinicalkey.com ] – and publishes nearly 2,200 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and over 25,000 book titles,
including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC [http://www.reedelsevier.com ], a
world-leading provider of professional information solutions in the Science, Medical,
Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed
Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange),
RUK and ENL (New York Stock Exchange).
Media contact Amy Burnis Director, Strategic Communications Elsevier +1-617-803-8344 firstname.lastname@example.org